msk-2206

Small moleculeexperimental

Clinical trial activity

49 trials · 30 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Apr 1, 2008 (NCT00670488)

Timeline

2000s

Jan 1, 2008
Earliest Phase 1 Sponsor(trial)

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Allosteric AKT inhibitor.

Chemistry & pharmacology

Loading structure…

SMILES

NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1

Mol. weight: 407.48 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL1079175 ↗

Also known as

mk2206
mk2206
mk2206
mk 2206
mk-2206
mk-2206
mk-2206
mk-2206
msk-2206

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01802320	Phase 2	Mar 1, 2013	National Cancer Institute (NCI), University of Texas at Houston
NCT01776008	Phase 2	Jan 1, 2013	Mayo Clinic, National Cancer Institute (NCI)
NCT01859182	Phase 2	Jan 1, 2013	National Cancer Institute (NCI), Ohio State University
NCT01783171	Phase 1	Jan 1, 2013	Johns Hopkins University, National Cancer Institute (NCI)
NCT01705340	Phase 1	Sep 1, 2012	Cornell University, National Cancer Institute (NCI)
NCT01658943	Phase 2	Aug 1, 2012	National Cancer Institute (NCI), Southwest Oncology Group
NCT01604772	Phase 2	Jul 1, 2012	National Cancer Institute (NCI)
NCT01519427	Phase 2	Jan 1, 2012	National Cancer Institute (NCI), University of South Florida
NCT01481129	Phase 2	Dec 1, 2011	Centre Leon Berard, National Cancer Institute (NCI)
NCT01480154	Phase 1	Nov 23, 2011	National Cancer Institute (NCI), Rutgers University
NCT01466868	Phase 2	Nov 1, 2011	Centre Leon Berard, National Cancer Institute, France
NCT01369849	Phase 1/Phase 2 (Phase 2)	Sep 1, 2011	National Cancer Institute (NCI)
NCT01370070	Phase 2	Jul 1, 2011	Chinese University of Hong Kong
NCT01248247	Phase 2	Jun 1, 2011	GlaxoSmithKline, Merck, National Cancer Institute (NCI), Novartis, University of Texas at Houston
NCT01344031	Phase 1	Apr 21, 2011	National Cancer Institute (NCI), Washington University in St. Louis
NCT01349933	Phase 2	Apr 1, 2011	Mayo Clinic, National Cancer Institute (NCI)
NCT01425879	Phase 2	Apr 1, 2011	National Cancer Institute (NCI), Ohio State University
NCT01283035	Phase 2	Apr 1, 2011	Harvard University, National Cancer Institute (NCI)
NCT01319539	Phase 2	Apr 1, 2011	National Cancer Institute (NCI), Yeshiva University
NCT01235897	Phase 1	Mar 1, 2011	Merck, University of California, San Francisco

Showing 20 of 49 trials

Page 1 / 3

Organizations

Research & Development (30)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
National Cancer Institute (NCI)	Government	32	31	2	2010
Merck	For profit	12	7	2	2008
University of Texas at Houston	Academic/Hospital	7	1	2	2010
Cornell University	Academic/Hospital	4	2	2	2010
Harvard University	Academic/Hospital	3	1	1	2010
Centre Leon Berard	Academic/Hospital	2	1	1	2011
Mayo Clinic	Academic/Hospital	2	0	1	2011
Ohio State University	Academic/Hospital	2	0	1	2011
Southwest Oncology Group	Academic/Hospital	2	0	1	2011
University of California, San Francisco	Academic/Hospital	2	1	2	2010
Vanderbilt University	Academic/Hospital	2	2	2	2010
AstraZeneca	For profit	1	0	1	2009
Chinese University of Hong Kong	Academic/Hospital	1	1	1	2011
ECOG-ACRIN Cancer Research Group	Academic/Hospital	1	0	1	2010
GlaxoSmithKline	For profit	1	0	1	2011
Johns Hopkins University	Academic/Hospital	1	0	1	2013
National Cancer Institute, France	Government	1	0	1	2011
National Institutes of Health (NIH)	Government	1	0	1	2011
National Taiwan University	Academic/Hospital	1	1	1	2010
Novartis	For profit	1	0	1	2011

30 organizations

Page 1 / 2